4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT)

Historical Holders from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
FDMT on Nasdaq
Shares outstanding
46,691,176
Price per share
$7.50
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
39,480,310
Total reported value
$343,063,021
% of total 13F portfolios
0%
Share change
-867,177
Value change
-$4,202,043
Number of holders
128
Price from insider filings
$7.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 10% 0% $15,056,434 -$655,031 4,632,749 -4.2% BVF PARTNERS L P/IL 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $14,835,818 4,564,867 RA Capital Management, L.P. 31 Dec 2024
GOLDMAN SACHS GROUP INC 9.6% $14,376,165 4,423,435 THE GOLDMAN SACHS GROUP, INC. 31 Dec 2024
Novo Holdings A/S 6.8% $27,590,750 3,175,000 Novo Holdings A/S 13 Oct 2025
BlackRock, Inc. 6.6% -15% $26,613,959 -$4,803,137 3,062,596 -15% BlackRock, Inc. 30 Sep 2025
JANUS HENDERSON GROUP PLC 4.9% $7,319,780 2,252,240 JANUS HENDERSON GROUP PLC 31 Dec 2024
Venrock Healthcare Capital Partners III, L.P. 1.5% -82% $2,202,200 -$7,393,006 677,600 -77% Venrock Healthcare Capital Partners III, L.P. 31 Mar 2025
Deep Track Capital, LP 1.3% $1,982,175 609,900 Deep Track Capital, LP 31 Dec 2024
As of 30 Sep 2025, 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 128 institutional shareholders filing 13F forms. They hold 39,480,310 shares. of 46,691,176 outstanding shares (85%) .

Top 25 institutional shareholders own 76% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BVF INC/IL 9.9% 4,629,289 0% 1.6% $40,228,521
RA CAPITAL MANAGEMENT, L.P. 9.8% 4,563,211 0% 0.49% $39,654,304
GOLDMAN SACHS GROUP INC 8.8% 4,128,416 -0.74% 0.01% $35,875,935
BlackRock, Inc. 8.3% 3,869,130 -3.5% 0% $33,622,738
VANGUARD GROUP INC 5.5% 2,575,122 -5.9% 0% $22,377,810
NOVO HOLDINGS A/S 4.3% 2,000,000 0% 1.1% $17,380,000
JANUS HENDERSON GROUP PLC 3.8% 1,753,367 -0.06% 0.01% $15,236,691
FEDERATED HERMES, INC. 3.4% 1,594,832 -4.3% 0.02% $13,859,090
MILLENNIUM MANAGEMENT LLC 2.5% 1,149,401 -23% 0.01% $9,988,295
ARMISTICE CAPITAL, LLC 2.3% 1,096,000 +265% 0.3% $9,524,240
GEODE CAPITAL MANAGEMENT, LLC 2% 913,519 -0.55% 0% $7,940,280
STATE STREET CORP 1.9% 903,774 -6% 0% $7,853,796
MORGAN STANLEY 1.8% 835,911 -9.6% 0% $7,264,066
BANK OF AMERICA CORP /DE/ 1.8% 819,266 -8.7% 0% $7,119,421
Assenagon Asset Management S.A. 1.4% 663,657 +2.3% 0.01% $5,767,179
TWO SIGMA ADVISERS, LP 1.2% 549,700 -26% 0.01% $4,776,893
DEUTSCHE BANK AG\ 1.2% 543,331 +139% 0% $4,721,546
JPMORGAN CHASE & CO 1.1% 513,515 -42% 0% $4,462,445
ArrowMark Colorado Holdings LLC 1.1% 504,115 -2% 0.08% $4,380,759
RAYMOND JAMES FINANCIAL INC 1% 471,270 +3.5% 0% $4,095,336
NORTHERN TRUST CORP 0.72% 335,586 +2% 0% $2,916,243
Peapod Lane Capital LLC 0.69% 322,081 +1.1% 2.5% $2,798,683
RENAISSANCE TECHNOLOGIES LLC 0.67% 313,186 +169% 0% $2,721,586
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.66% 305,857 +3.7% 0% $2,657,897
TWO SIGMA INVESTMENTS, LP 0.59% 273,496 -49% 0% $2,376,680

Institutional Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 314,050 $2,354,894 -$2,636,178 $7.50 5
2025 Q3 39,480,310 $343,063,021 -$4,202,043 $8.69 128
2025 Q2 40,369,426 $149,859,289 -$9,235,482 $3.71 117
2025 Q1 43,058,381 $139,823,044 -$22,403,324 $3.23 122
2024 Q4 46,814,824 $260,642,119 -$79,332,651 $5.57 140
2024 Q3 57,948,767 $626,374,639 -$34,446,524 $10.81 135
2024 Q2 57,307,189 $1,203,018,791 +$3,520,347 $20.99 138
2024 Q1 56,228,706 $1,790,823,856 +$449,592,828 $31.86 146
2023 Q4 42,433,937 $859,819,319 +$24,792,782 $20.26 111
2023 Q3 41,913,779 $533,559,212 +$5,221,810 $12.73 110
2023 Q2 41,248,927 $745,334,512 +$197,052,931 $18.07 100
2023 Q1 30,404,028 $522,337,328 +$34,968,755 $17.19 94
2022 Q4 28,011,571 $622,110,124 +$47,681,640 $22.21 97
2022 Q3 26,181,987 $210,496,945 +$1,974,268 $8.04 84
2022 Q2 26,027,061 $181,670,139 -$2,172,042 $6.98 86
2022 Q1 26,134,053 $395,189,957 +$20,420,485 $15.12 76
2021 Q4 24,702,968 $541,790,297 +$81,054,878 $21.94 77
2021 Q3 18,711,908 $504,667,012 +$57,523,278 $26.97 61
2021 Q2 16,612,608 $400,026,000 +$731,531 $24.08 54
2021 Q1 15,384,514 $664,816,567 +$34,097,345 $43.38 63
2020 Q4 14,593,004 $602,432,000 +$578,482,000 $41.45 51